Shineyo Medical to Showcase RhythPulse® PFA System at Jiangcheng International Congress of Cardiology 2026
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
Click the blue text to follow us
SHINEYOMEDICAL
June 26-28, 2026Jiangcheng International Congress of Cardiology 2026 (JICC 2026)To be held in Wuhan. Adhering to the mission of “Focusing on the Frontier, Leading Innovation, Collaborating for Mutual Benefit, and Serving Health,” the conference is themed around “Joint, Innovation, Communication, and Collaboration.” It features over 30 specialized forums covering a wide range of topics, including coronary artery disease, cardiac rhythm disorders, heart failure, structural heart disease, and cardiovascular diseases. Through keynote lectures, case discussions, and live surgical demonstrations, the event offers attendees a high-level academic feast.
Venue:
⭐️June 26-28 ShineyoMedical Booth:Wuhan Eurasia Convention & Exhibition International Hotel, 3rd Floor, B16 (Opposite Shanghai Hall 2)
⭐️ The location of the star in the image below ⬇️, as shown in the figure. You are welcome to visit!
Floor Plan of the 3rd Floor Conference Room
View Conference Agenda
About ShineyoMedical
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical’s RhythPulse®-PFA system is the first pulsed field ablation (PFA) system approved in China that integrates multi-channel, large-lesion, and targeted ablation capabilities. It is primarily used to treat drug-refractory, recurrent atrial fibrillation and other tachyarrhythmias. Its core advantages include:
Overall Layout Design:Utilizing the world’s first 10mm circular ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, increasing ablation efficiency by more than threefold compared to traditional techniques.
Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective ablation. Postoperative plasma free hemoglobin levels decreased by 50%.
Excellent Clinical Validation:In 151 clinical trial cases, the immediate success rate was 100%, and the success rate of atrial fibrillation treatment at 12 months post-operation reached as high as 85.07%, achieving an internationally leading standard.
Learn More
Please followShineyoMedical[Official Account]